共 4 条
[1]
Phase II study of the multitargeted antifolate LY231514 (ALIMTAâ¢; MTA; pemetrexed disodium) in patients with advanced pancreatic cancer.[J].K. D. Miller;J. Picus;C. Blanke;W. John;J. Clark;L. N. Shulman;D. Thornton;E. Rowinsky;P. J. Loehrer Sr.Annals of Oncology.2000, 1
[2]
Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514; Pemetrexed disodium; ALIMTA⢠and cisplatin: A multicenter phase II trial.[J].C. Manegold;U. Gatzemeier;J. von Pawel;R. Pirker;R. Malayeri;J. Blatter;K. Krejcy.Annals of Oncology.2000, 4
[3]
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation
[J].
CANCER CHEMOTHERAPY AND PHARMACOLOGY,
1999, 44 (05)
:372-380
Rinaldi, DA
;
Kuhn, JG
;
Burris, HA
;
Dorr, FA
;
Rodriguez, G
;
Eckhardt, SG
;
Jones, S
;
Woodworth, JR
;
Baker, S
;
Langley, C
;
Mascorro, D
;
Abrahams, T
;
Von Hoff, DD
.
[4]
Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: An NCIC Clinical Trials Group study
[J].
ANNALS OF ONCOLOGY,
1999, 10 (10)
:1175-1179
Cripps, C
;
Burnell, M
;
Jolivet, J
;
Batist, G
;
Lofters, W
;
Dancey, J
;
Iglesias, J
;
Fisher, B
;
Eisenhauer, EA
.